Urticaria Clinical Trial
Official title:
The Use of Doxepin for Urticaria in the Emergency Department
NCT number | NCT05115136 |
Other study ID # | 1576028 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | May 23, 2022 |
Est. completion date | July 1, 2023 |
Isolated urticaria in the emergency department is widely treated by physicians with histamine blocking agents such as diphenhydramine, cetirizine, and cimetidine. Doxepin is a tricyclic antidepressant that has been shown to have much higher concentrations of histamine blocking activity and therefore may be useful in treating urticaria. The purpose of this study is to compare the effectiveness of using doxepin verses a traditional medication, diphenhydramine (Benadryl), in the treatment of isolated urticaria in the emergency department.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | July 1, 2023 |
Est. primary completion date | January 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Between 18-65 years of age - Presenting to Upstate Adult Emergency Department at either the Downtown or Community campuses. - Diagnosed with isolated/acute urticaria - Requires treatment with antihistamines to alleviate symptoms Exclusion Criteria: - Pregnant women - Prisoners - Patients with altered mental status/have impaired decision-making capacity. - Presenting with symptoms suggesting life threatening illness or anaphylaxis. - Patients who have received any antihistamine (H1 antagonist) within the past 2 hours via any route of administration. - Patients who have received an H2 antagonist within the past 2 hours. - Patient received steroids by any route within the past 4 hours. - Patient received epinephrine within the past 20 minutes. - Patients currently taking concomitant p-glycoprotein inhibitors. - Patients on any of the following CYP2D6 inhibitors: Bupropion, Fluoxetine, Paroxetine, Quinidine, Tipranavir. - Patients with a history of serotonin syndrome. - Patients currently taking another tricyclic antidepressant, selective serotonin reuptake inhibitor, and/or serotonin-norepinephrine reuptake inhibitor. - Patients who have a condition where an antihistamine may be contraindicated. - Patients with a contraindication to anticholinergic medications. - History of adverse effects to tricyclic antidepressants or antihistamines. - Patient who, based on their medical history or in the opinion of the clinician, have chronic urticaria, urticaria refractory to antihistamines, or dermatological disease that interferes with evaluation of a therapeutic response. - Patients taking antileukotriene compounds (montelukast), calcineurin inhibitors (tacrolimus) or anti-serotonin agents (cyproheptadine) |
Country | Name | City | State |
---|---|---|---|
United States | SUNY Upstate Medical University | Syracuse | New York |
Lead Sponsor | Collaborator |
---|---|
State University of New York - Upstate Medical University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improvement of urticaria | Improvement of urticaria based on pruritis score. Scale is from 1-5, lower the score the better. | 1 hour after med administration, 2 hours after administration, and prior to discharge. | |
Primary | Improvement of urticaria | Improvement of urticaria based percent of body area affected. Scale being utilized is the % of body area chart. | 1 hour after med administration, 2 hours after administration, and prior to discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03693625 -
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study
|
Phase 2 | |
Recruiting |
NCT03545464 -
COrticosteroids in acUte uRticAria in emerGency dEpartment
|
Phase 3 | |
Completed |
NCT00541255 -
A Long-Term Examination of Asthma From Childhood Through Adolescence
|
||
Not yet recruiting |
NCT00163839 -
The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema
|
N/A | |
Terminated |
NCT00069329 -
Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
|
N/A | |
Completed |
NCT00876369 -
Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema
|
||
Terminated |
NCT00199238 -
Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria
|
Phase 2 | |
Completed |
NCT02576041 -
Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria
|
Phase 4 | |
Completed |
NCT00724698 -
Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
|
||
Completed |
NCT02238249 -
Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria
|
N/A | |
Completed |
NCT00001150 -
Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers
|
N/A | |
Completed |
NCT03296358 -
Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.
|
N/A | |
Completed |
NCT00130234 -
Effect of Anti-IgE in Chronic Urticaria
|
Phase 2 | |
Completed |
NCT00795158 -
How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)
|
Phase 3 | |
Completed |
NCT00368823 -
A Trial of Point of Care Information in Ambulatory Pediatrics
|
Phase 3 | |
Completed |
NCT02424799 -
Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264
|
Phase 1 | |
Completed |
NCT01371877 -
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
|
N/A | |
Completed |
NCT00751218 -
A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)
|
Phase 4 | |
Completed |
NCT03137069 -
A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
|
Phase 2 | |
Terminated |
NCT02382562 -
Brief Behavioral Activation Intervention for Depressed Asthma and Urticaria Patients
|
N/A |